Pfizer Gains Multiple ABRYSVO Approvals as FDA Mandates GBS Warning Across RSV Vaccine Labels

Post-approval labeling obligations for RSV vaccines sharpened considerably when Pfizer's ABRYSVO and GSK's Arexvy received a mandated Guillain-Barré Syndrome (GBS) warning in their prescribing information, effective January 7, 2025, a regulatory action that signals heightened FDA scrutiny of biologics safety signals emerging after initial licensure.

ABRYSVO holds three distinct indications under STN 125769 and STN 125768: active immunization of pregnant individuals at 32 through 36 weeks gestational age for prevention of lower respiratory tract disease (LRTD) in infants from birth through six months; active immunization for LRTD prevention in individuals 60 years and older; and active immunization for individuals aged 18 through 59 at increased risk for RSV-related LRTD. The breadth of the indication set, spanning maternal immunization through high-risk adult populations, places ABRYSVO among the more complex biologics lifecycle management cases currently active in the FDA's biologics portfolio.

The approval history reflects sustained post-market regulatory activity. Since initial licensure on May 31, 2023, FDA has issued at least nine subsequent approval letters across both STNs through December 2025, covering supplemental submissions that include labeling revisions, manufacturing changes, and indication expansions. For QA directors tracking 21 CFR Part 601 compliance, the cadence of supplemental approvals underscores the resource intensity of maintaining a biologics license across multiple population segments and evolving safety data.

The GBS warning addition is the most operationally significant labeling event in ABRYSVO's post-approval history to date. FDA's decision to mandate the warning concurrently across two competing RSV vaccines points to a class-level safety signal rather than a product-specific finding, a distinction that regulatory affairs teams managing RSV vaccine programs should document carefully within their pharmacovigilance frameworks. Demographic subgroup data referenced in the Clinical Review Memo for both STNs remains a standing resource for teams conducting benefit-risk assessments tied to label updates.

The December 19, 2025 approval letter represents the most recent regulatory action on record, indicating that ABRYSVO's supplemental submission activity remains ongoing as Pfizer continues to manage the product through its commercial lifecycle.

Source: U.S. Food and Drug Administration, Vaccines, Blood and Biologics product page via FDA.gov RSS Feed, July 10, 2026.